These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36323103)

  • 1. Mathematical and experimental validation of an approach for simultaneously determining the binding parameters of two drugs to a receptor.
    Qiao S; Ou Y; Liu L; Wang S; Bian L; Zhao X
    J Chromatogr A; 2022 Dec; 1685():463593. PubMed ID: 36323103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.
    Gatfield J; Mueller Grandjean C; Sasse T; Clozel M; Nayler O
    PLoS One; 2012; 7(10):e47662. PubMed ID: 23077657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes.
    Lepist EI; Gillies H; Smith W; Hao J; Hubert C; St Claire RL; Brouwer KR; Ray AS
    PLoS One; 2014; 9(1):e87548. PubMed ID: 24498134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct ETA receptor binding mode of macitentan as determined by site directed mutagenesis.
    Gatfield J; Mueller Grandjean C; Bur D; Bolli MH; Nayler O
    PLoS One; 2014; 9(9):e107809. PubMed ID: 25226600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
    Bedan M; Grimm D; Wehland M; Simonsen U; Infanger M; Krüger M
    Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):103-113. PubMed ID: 29719121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional estimation of endothelin-1 receptor antagonism by bosentan, macitentan and ambrisentan in human pulmonary and radial arteries in vitro.
    Angus JA; Soeding PF; Hughes RJA; Wright CE
    Eur J Pharmacol; 2017 Jun; 804():111-116. PubMed ID: 28300593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta-Analysis of 4894 Patients From 24 Randomized Double-Blind Placebo-Controlled Clinical Trials.
    Wei A; Gu Z; Li J; Liu X; Wu X; Han Y; Pu J
    J Am Heart Assoc; 2016 Oct; 5(11):. PubMed ID: 27912207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
    Grünig E; Ohnesorge J; Benjamin N; Burhenne J; Enderle Y; Egenlauf B; Fischer C; Harutyunova S; Huppertz A; Klose H; Haefeli WE
    Respiration; 2017; 94(1):26-37. PubMed ID: 28494463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model.
    Englert L; Stadlbauer C; Spaeth M; Hofmann HS; Schneider C; Hatz RA; Preissler G; Michel S; Golovchenko S; Ried M; Hoenicka M
    Pulm Pharmacol Ther; 2021 Feb; 66():101985. PubMed ID: 33359621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis].
    Fu WH; Chen PL; Xia JL; Fu L; Shen Y; He WJ; Chen YH; Ren N; Jiang Q; Ma R; Wang T; Wang XN; Zhang NF; Liu CL
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Feb; 45(2):158-170. PubMed ID: 35135085
    [No Abstract]   [Full Text] [Related]  

  • 11. The Clinical Efficacy of Endothelin Receptor Antagonists in Patients with Pulmonary Arterial Hypertension.
    Maki H; Hara T; Tsuji M; Saito A; Minatsuki S; Inaba T; Amiya E; Hosoya Y; Hatano M; Morita H; Yao A; Kinugawa K; Komuro I
    Int Heart J; 2020; 61(4):799-805. PubMed ID: 32728000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening potential ligands of endothelin receptor A from Choerospondias axillaris and evaluation of their drug-like properties by affinity chromatographic methods.
    Ji X; Ge L; Ma R; Zhang X; Li J; Song D; Pei L; Sun F; Zhao Q
    J Pharm Biomed Anal; 2023 Mar; 226():115240. PubMed ID: 36657350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring drug-protein interactions using the relationship between injection volume and capacity factor.
    Zhao X; Li Q; Chen J; Xiao C; Bian L; Zheng J; Zheng X; Li Z; Zhang Y
    J Chromatogr A; 2014 Apr; 1339():137-44. PubMed ID: 24666938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelin receptor antagonists alleviate blood-brain barrier disruption and cerebral edema in a mouse model of traumatic brain injury: A comparison between bosentan and ambrisentan.
    Michinaga S; Inoue A; Yamamoto H; Ryu R; Inoue A; Mizuguchi H; Koyama Y
    Neuropharmacology; 2020 Sep; 175():108182. PubMed ID: 32561219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the protective effects of selective endothelin-a receptor antagonist, ambrisentan, and dual endothelin-A/B receptor antagonist, bosentan, in experimental renal ischemia reperfusion injury.
    Kazimoglu H; Uysal E; Dokur M; Gurer AO; Batcioglu K; Uyumlu BA; Petekkaya E; Karadag M
    Bratisl Lek Listy; 2020; 121(8):547-553. PubMed ID: 32726116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bladder endothelin-1 receptor binding of bosentan and ambrisentan.
    Osano A; Yokoyama Y; Hayashi H; Itoh K; Okura T; Deguchi Y; Ito Y; Yamada S
    J Pharmacol Sci; 2014; 124(1):86-91. PubMed ID: 24389822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous LC-MS analysis of plasma concentrations of sildenafil, tadalafil, bosentan, ambrisentan, and macitentan in patients with pulmonary arterial hypertension.
    Tanaka S; Uchida S; Hakamata A; Miyakawa S; Odagiri K; Inui N; Watanabe H; Namiki N
    Pharmazie; 2020 Jun; 75(6):236-239. PubMed ID: 32539916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dynamics of the clinical functional and hemodynamic profile of patients with pulmonary arterial hypertension with initial monotherapy with endothelin receptor antagonists: bosentan vs. macitentan].
    Martynyuk TV; Aleevskaya AM
    Kardiologiia; 2020 Aug; 60(7):28-35. PubMed ID: 33155938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of selective ligands targeting two GPCRs by receptor-affinity chromatography coupled with high-throughput sequencing techniques.
    Liang Q; Zhao X; Fu X; Wang J; Li Q; Zhao X
    Bioorg Chem; 2021 Jul; 112():104986. PubMed ID: 34029972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological counseling in hepatotoxicity induced by macitentan and selexipag:  a case report.
    Lattanzio M; Ferrari M; Martini S; Ceriani F; Imporzani A; Marino F; De Ponti R; Cosentino M
    J Med Case Rep; 2022 Oct; 16(1):385. PubMed ID: 36258237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.